Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TTN7Y4P)

• DTT Name: Sodium/glucose cotransporter 2 (SLC5A4) DTT Info
• Gene Name: SLC5A4

Molecule-Related Drug & Molecule List

4 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
RG7201	DMJRFYB	Type-2 diabetes	5A11	Phase 3	[1]
SaxaDapa FDC	DMAPRWV	Diabetic complication	5A2Y	Phase 3	[2]
Remogli ozin-etabonate	DMZFV3E	Type-2 diabetes	5A11	Phase 2	[3]
Remogliflozin etabonate	DMW4YK1	Type-1/2 diabetes	5A10-5A11	Phase 2	[4]

1 Discontinued Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ponalrestat	DM04ZUW	Gout	FA25	Discontinued in Phase 3	[5]

References

• [1] Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study. Cardiovasc Diabetol. 2014 Mar 28;13:65.
• [2] Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for type 2 diabetes. Cardiol Rev. 2010 Jul-Aug;18(4):213-7.
• [3] Safety, pharmacokinetics and pharmacodynamics of remogliflozin etabonate, a novel SGLT2 inhibitor, and metformin when co-administered in subjects with type 2 diabetes mellitus. BMC Pharmacol Toxicol.2013 Apr 30;14:25.
• [4] Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
• [5] Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2009).